TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02929979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Participants will complete 22.5 hours of cognitive training exercises over 6-weeks (training 5 times a week) using an app-based program, BrainHQ (BPI/Posit Science, San Francisco). BrainHQ is based on a previous neuroscience-based cognitive training program shown to improve cognition in several different randomized controlled studies with other clinical populations. The investigators will use a suite of BrainHQ exercises designed to target and ameliorate cognitive disruptions in 4 cognitive domains (see main outcome). The investigators will employ basic exercises that focus on increasing processing efficiency in the auditory and visual perceptual and working memory domains, as well as exercises that target impulsivity and cognitive biases. Exercises will be packaged into 4 modules (attention skills, memory skills, executive functioning skills, cognitive control skills) comprised of 4 exercises each. All participants will progress through the same fixed schedule of modules.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive training placebo control
Description: Participants will play a rotating set of commercial computer games at the same dose and frequency as the cognitive training. The investigators selected this control activity because it mirrors the game-like properties of the cognitive training and it will be used to control for contact with research personnel and for the non-specific effects of participant motivation and engagement with daily computerized activities. It also allows for a double blind study design. Games from the website Sporcle will be used and an online account can be created for each participant.
Study: NCT01985802

Intervention type: OTHER
Group type: OTHER
Intervention: Pacing
Study: NCT03704220

Intervention type: DRUG
Group type: OTHER
Intervention: Warfarin
Description: Removal of anticoagulation with warfarin
Study: NCT00996320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced work hour schedule
Description: Interns on the intervention schedule work an average of 60 hours per week over 4 weeks, with maximum shift length 16 hours.
Study: NCT04079907

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone
Description: This intervention will take their respective supplement for 14 days, then will be followed for up to 1 year during routine clinic visits.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This intervention will take their respective supplement for 14 days, then will be followed for up to 1 year during routine clinic visits.
Study: NCT04602507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Routinary care offered in the hospital plus ivermectin 400 µg/kg (2 drops per kg) orally in a single dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Routinary care offered in the hospital plus placebo (2 drops per kg) orally in a single dose
Study: NCT01694485

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abrilumab
Description: Administered by subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abrilumab
Description: Administered by subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abrilumab
Description: Administered by subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abrilumab
Description: Administered by subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Abrilumab
Description: Administered by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to abrilumab administered by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to abrilumab administered by subcutaneous injection
Study: NCT00852436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: Pregabalin capsules in 75 mg,dosing increment from 150, 300, to 600mg/day at weekly intervals,administered orally one (or two, or four) capsule(s), twice daily. Fixed schedule of dosing increment from 150, 300, to 600mg/day at weekly intervals, until the highest tolerated dose has been reached. A single downward dose titration will be allowed depending on tolerability, after which the patient will remain on this dosage for the rest of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo capsules in 75 mg,dosing increment from 150, 300, to 600mg/day at weekly intervals,administered orally one (or two, or four) capsule(s), twice daily. Fixed schedule of dosing increment from 150, 300, to 600mg/day at weekly intervals, until the highest tolerated dose has been reached. A single downward dose titration will be allowed depending on tolerability, after which the patient will remain on this dosage for the rest of the study.
Study: NCT02179983

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: 6 weeks of supervised exercise and education (pulmonary rehabilitation)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: 6 weeks of exercise and patient education following exacerbation (pulmonary rehabilitation)
Study: NCT03156764

Intervention type: OTHER
Intervention: Qp/Qs ratio monitoring
Description: Op/Qs -monitor will be calculated using SpO2 and cerebral oximetry Op/Qs -blood will be calculated using ABGA and VBGA
Study: NCT00000588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chelation therapy
Description: After an initial 21 day balance study to demonstrate that a selected dose of PIH produced sufficient iron excretion, patients were begun on chronic therapy. PIH or placebo were given on days 4 to 9 and days 13 to 18 in a randomized, double-blind, cross-over design.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chelation therapy
Description: After an initial 21 day balance study to demonstrate that a selected dose of PIH produced sufficient iron excretion, patients were begun on chronic therapy. PIH or placebo were given on days 4 to 9 and days 13 to 18 in a randomized, double-blind, cross-over design.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo given at same time points as the Intervetnion for each clinical condition.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given at same time points as the Intervetnion for each clinical condition.
Study: NCT03582332

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin SR, 75 Mg Oral Capsule, Extended Release
Description: Indomethacin SR, 75 Mg Oral Capsule, Extended Release orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin 25 Mg Oral Capsule
Description: Indomethacin 25 Mg Oral Capsule, 2 capsule orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib 90 mg
Description: Etoricoxib 90 mg once daily orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib 60 mg
Description: Etoricoxib 60 mg once daily orally
Study: NCT02767232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt-PA)
Description: Catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Anticoagulation Therapy
Description: Standard anticoagulation determined by physician for a period of 3-6 months
Study: NCT03689790

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sleeve gastrectomy
Description: sleeve gastrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastric bypass
Description: gastric bypass
Study: NCT00528242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLx-2101

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04211818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating Behavior
Description: A dietary book will be given to the patient and will be filled by this one during 14 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood glucose records
Description: A glycemic sensor will be placed at the back of the patient's arm
Study: NCT05106166

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy
Description: occupational therapy sessions are based on the joint attention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: occupational therapy sessions are based on the joint attention
Study: NCT03043547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nal-IRI
Description: nal-IRI \[Irinotecan liposome\] (80 mg/m2 as a 1.5 hour infusion)

Intervention type: DRUG
Group type: OTHER
Intervention: 5-FU
Description: 5-FU \[5-Fluorouracil\] (2400 mg/m2 as 46 hour infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU \[5-Fluorouracil\] (2400 mg/m2 as 46 hour infusion)

Intervention type: DRUG
Group type: OTHER
Intervention: leucovorin
Description: leucovorin (400 mg/m2 as 0.5 hour infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: leucovorin (400 mg/m2 as 0.5 hour infusion)
Study: NCT04098536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diesel exhaust
Description: Exposure to diesel exhaust fumes

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diesel exhaust
Description: Exposure to diesel exhaust fumes
Study: NCT03386422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MSC
Description: Mindfulness and Self-Compassion training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: Cognitive-behavioural techniques training
Study: NCT04677764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: Wii Fit balance board (Nintendo Inc., Kyoto, Japan).

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: physical therapy and occupational therapy exercises either at their own home or a gym

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: physical therapy and occupational therapy exercises either at their own home or a gym
Study: NCT04503330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: buccal mucosal graft to repair iatrogenic PUJO
Description: Augmented buccal mucosal graft anastomosis to repair iatrogenic PUJO or long segment ureteric stricture disease
Study: NCT02632136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAP Block Group
Description: Transversus Abdominus Plane (TAP) block: Bupivacaine (30 ml of 0.25%)is injected between internal oblique and transveralis facia. The location of needle and the bleb that is formed after the injection is inspected under diect laparoscopic vision.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peri-Portal Block Group
Description: 15 ml of 0.5% Bupivacaine is injected in the skin and subcutaneous tissue before inserting the ports. 7 ml out of it is injected at sub-umblical port and 4 ml each a the site of other two ports.
Study: NCT04132856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychosocial Navigator
Description: Services of psychosocial navigator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication of Summary Profile
Description: Both patient/caregiver dyad and HCPs will receive a summary of the PAT results and levels of depression and anxiety.
Study: NCT02899390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Before implementation of the National Diabetes Prevention Program, adaptations will be made in order to be culturally acceptable in the community taking in consideration the type of food they eat and their activities in the population.~The lifestyle intervention will be implemented by group and individual sessions and is aimed at achieving a 7% loss weight from baseline and 150 minutes per week of physical activity. Sessions will be held weekly in a period of 6 months. Individual sessions consist in nutritional counseling according to energy needs and food preferences of each participant.
Study: NCT01860976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02019810

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine and norepinephrine
Study: NCT01353495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APM Graft (BIOTAPE XMTM)
Description: Patients randomized to the APM group will, following surgical debridement for their diabetic foot wounds, receive a single application of an APM graft (BIOTAPE XMTM, Wright Medical Technology, USA) with dressing changes taking place weekly. All necrotic tissue will be removed from the wound prior to application. BIOTAPE XMTM will be sutured or stapled in place under a silver-based non-adherent dressing (Silverlon, Argenta Medical). Therapy will then be followed by a moisture-retentive dressing (hydrogel bolster) until complete epithelialization has occurred.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wound Debridement
Description: Wounds debrided in both arms of study

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wound Debridement
Description: Wounds debrided in both arms of study
Study: NCT00442806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of ADRC's
Description: ADRC's are injected

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Injection of Placebo
Description: Placebo is injected
Study: NCT02385097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine HCl 2%
Description: Single Administration (20mL) by Axillary Nerve Route

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.75%
Description: Single Administration (20mL) by Axillary Nerve Route
Study: NCT01474564

Intervention type: OTHER
Intervention: Blood draw
Description: Patients with pancreatic adenocarcinoma will be enrolled. Venous blood is collected in a standard 10 ml heparin blood collection tube. We may ask for blood samples at different times during the course of the study, specifically, before you start treatment and when your treatment changes. During the one year of the study, the physician anticipates blood samples will be collected a minimum of one and a maximum of four times. The amount of blood collected at any of these times will be 10 mL, about 1 tablespoon.
Study: NCT03992196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine 1 mg/24 h
Description: Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 1 mg/24 h (5 cm\^2 patch size).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine 2 mg/24 h
Description: Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 2 mg/24 h (10 cm\^2 patch size).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine 3 mg/24 h
Description: Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 3 mg/24 h (15 cm\^2 patch size).
Study: NCT00449150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix 78 mg + 78 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix 78 mg + 52 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04189848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.
Study: NCT01346085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNI free immunosuppression
Description: Immunosuppression consisted of: (i) pre-Tx rapamycin treatment (0.1 mg/kg/day) for at least 30 days; (ii) induction therapy with ATG (1.5 mg/kg/day for 4 days starting at day -1) and a steroid bolus (methyl-prednisolone 500 mg, day -1) plus low dose steroids (prednisone, 10 mg/day) and interleukin-1 (IL-1) receptor antagonist (100 mg/day) for 2 weeks (with ATG and steroid bolus administered only prior to the 1st islet infusion; (iii) maintenance with rapamycin (0.1 mg/kg/day) plus mycophenolate mofetil (2 g/day).
Study: NCT01029353

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparotomy
Description: Initial laparotomy will be performed. Standard procedures will be used, including inspection of the bowel with removal of diseased areas, creation of stoma(s), and other procedures deemed indicated by the surgeon.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparotomy
Description: Initial laparotomy will be performed. Standard procedures will be used, including inspection of the bowel with removal of diseased areas, creation of stoma(s), and other procedures deemed indicated by the surgeon.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drainage
Description: Initial drainage will involve placing a Penrose drain in the abdomen.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drainage
Description: Initial drainage will involve placing a Penrose drain in the abdomen.
Study: NCT02377336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-6615
Description: GS-6615 tablets administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match GS-6615 tablets administered orally
Study: NCT01220206

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo capsules daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: One POMx capsule daily
Description: One POMx capsule, one placebo capsule daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 POMx Capsules
Description: 2 POMx Capsules daily
Study: NCT00379756

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEVITRA (vardenafil)
Description: active comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo comparator
Study: NCT04162626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive home visits to new families
Description: The new families are offered home visits by a public health nurse from 28 weeks in pregnancy until the child is two years old. The number of home visits depends on the families needs and wishes. They also get the usual follow up from the Child health center.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Follow up at the Child health center according to national regulations
Study: NCT06441396

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation
Description: In the study, the VTR guru was given video footage of 15 exercises previously recorded on camera. The individuals in this group were made to do the exercises together online via the WhatsApp program. Exercises in both groups were planned for 6 weeks, 3 days a week, 25-45 minutes. The main program consists of 15 calisthenic exercises involving the lower extremity, upper extremity and trunk large muscle groups. Exercises in both groups were planned for 6 weeks, 3 days a week, 25-45 minutes. The number of repetitions of each exercise started with 10 and was increased by 5 repetitions every two weeks until it reached 20 repetitions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video-based rehabilitation (VTR)
Description: In the study, the VTR guru was given video footage of 15 exercises previously recorded on camera. Participants were asked to exercise by watching these videos. In addition, these individuals were interviewed once a week to check the progress of the exercise program. Video images were sent to the intervention group for informational purposes, and the individuals in this group were made to do the exercises together online via the WhatsApp program.
Study: NCT04346706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extraction and Implant insertion (test)
Description: The surgical procedure was conducted under local anesthesia. Intrasulcular incisions were performed around the mesial and distal tooth to the implant recipient site. Buccal and palatal mucoperiosteal flaps were elevated. Tooth extractions were carried out atraumatically using periotomes. Implant site preparation was completed in compliance with the general surgical principles and protocols defined by the manufacturer and screw-shaped implants (UFII, DIO™) were inserted at no less than 35 Ncm. Final insertion torque (IT) was measured and recorded using a manual hand wrench (DIO™). Resonance frequency analysis (RFA) was performed using an Osstell device (Sävedalen, Sweden). For each implant, three Implant Stability Quotient (ISQ) readings were recorded by the same operator to calculate the mean ISQ, at implant placement (T0) and 3 months after implant insertion (T3) prior to final abutment torque and crown cementation.~Absorbable interrupted 4.0 sutures were used for flap closure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant insertion (control)
Description: The surgical procedure was conducted under local anesthesia. Intrasulcular incisions were performed around the mesial and distal tooth to the implant recipient site. Buccal and palatal mucoperiosteal flaps were elevated, the implant site preparation was completed in compliance with the general surgical principles and protocols defined by the manufacturer and screw-shaped implants (UFII, DIO™) were inserted at no less than 35 Ncm. Final insertion torque (IT) was measured and recorded using a manual hand wrench (DIO™). Resonance frequency analysis (RFA) was performed using an Osstell device (Sävedalen, Sweden). For each implant, three Implant Stability Quotient (ISQ) readings were recorded by the same operator to calculate the mean ISQ. This was done at implant placement (T0) and 3 months after implant insertion (T3) prior to final abutment torque and crown cementation.~Absorbable interrupted 4.0 sutures were used for flap closure.